Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ATLAS
NCT02663297Phase 1Active, not recruiting
- Sponsor
- UNC Lineberger Comprehensive Cancer Center
- Start
- Jun 2016
- Primary completion
- Jan 2021
- Modality
- CAR-T Cells
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of ATLCAR in lymphoma, sponsored by UNC Lineberger Comprehensive Cancer Center. Primary endpoint: Number of Participants With Adverse Events as a Measure of Safety and Tolerability at 6 weeks. Started Jun 2016; status: active, not recruiting.
02
Drugs
ATLCAR
03
Conditions
lymphoma
Beyond the preview
Go deeper on NCT02663297.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02663297.